Literature DB >> 11292752

Effector mechanisms of protection against Pseudomonas aeruginosa keratitis in immunized rats.

A Thakur1, J Kyd, M Xue, M D Willcox, A Cripps.   

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen which causes sight-threatening corneal infections in humans. The purpose of this study was to evaluate various immunization routes that may provide protection against Pseudomonas keratitis and to define the molecular mechanisms involved in the protection. Sprague-Dawley rats (10 to 12 weeks old) were immunized using paraformaldehyde-killed P. aeruginosa (strain 6206) via oral, nasal, and intra-Peyer's patch (IPP) routes followed by an ocular topical booster dose. Scratched corneas were challenged with an infective dose of P. aeruginosa. Following clinical examination, eyes were enucleated for histology, polymorphonuclear leukocyte (PMN) quantitation, bacterial count, enzyme-linked immunosorbent assay, and RNase protection assay. PMN infiltration was higher early (4 h) during the infection in immunized rats than in nonimmunized rats. Later during the infection, the number of PMNs diminished in immunized rats while in nonimmunized animals the number of PMNs continued to increase. Bacteria were cleared much faster from immunized groups than from the nonimmunized group, and the nasally immunized group had the most efficacious response among the immunized groups. Nasal and IPP immunization groups had increased cytokine expression of interleukin-2 (IL-2) and IL-5 and differed from each other for IL-6. All three immunized groups had significantly reduced IL-1 beta levels when compared with the nonimmunized rats and a significantly altered profile for CINC-1 expression. This study has shown that the route of immunization modulates the inflammatory response to ocular P. aeruginosa infection, thus affecting the severity of keratitis and adverse pathology, with nasal immunization being the most effective.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292752      PMCID: PMC98288          DOI: 10.1128/IAI.69.5.3295-3304.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Macrophage inflammatory protein-2 is a mediator of polymorphonuclear neutrophil influx in ocular bacterial infection.

Authors:  K A Kernacki; R P Barrett; J A Hobden; L D Hazlett
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

2.  Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production.

Authors:  M Yanagita; T Hiroi; N Kitagaki; S Hamada; H O Ito; H Shimauchi; S Murakami; H Okada; H Kiyono
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

3.  Increased severity of Pseudomonas aeruginosa corneal infection in strains of mice designated as Th1 versus Th2 responsive.

Authors:  L D Hazlett; S McClellan; B Kwon; R Barrett
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-03       Impact factor: 4.799

4.  Prolonged elevation of IL-1 in Pseudomonas aeruginosa ocular infection regulates macrophage-inflammatory protein-2 production, polymorphonuclear neutrophil persistence, and corneal perforation.

Authors:  X L Rudner; K A Kernacki; R P Barrett; L D Hazlett
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

5.  Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection.

Authors:  M M Moon; L D Hazlett; R E Hancock; R S Berk; R Barrett
Journal:  Invest Ophthalmol Vis Sci       Date:  1988-08       Impact factor: 4.799

6.  Topical immunotherapy for pseudomonas keratitis in rabbits: use of antilipopolysaccharide plasma.

Authors:  N H Welsh; A J Rauch; S L Gaffin
Journal:  Br J Ophthalmol       Date:  1984-11       Impact factor: 4.638

7.  Cellular and extracellular myeloperoxidase in pyogenic inflammation.

Authors:  P P Bradley; R D Christensen; G Rothstein
Journal:  Blood       Date:  1982-09       Impact factor: 22.113

8.  Immunization against experimental Pseudomonas aeruginosa and Serratia marcescens keratitis. Vaccination with lipopolysaccharide endotoxins and proteases.

Authors:  A S Kreger; D M Lyerly; L D Hazlett; R S Berk
Journal:  Invest Ophthalmol Vis Sci       Date:  1986-06       Impact factor: 4.799

9.  Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells.

Authors:  K W Beagley; J H Eldridge; F Lee; H Kiyono; M P Everson; W J Koopman; T Hirano; T Kishimoto; J R McGhee
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

10.  Systemic tolerance and secretory immunity after oral immunization.

Authors:  S J Challacombe; T B Tomasi
Journal:  J Exp Med       Date:  1980-12-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Corneal ulceration in pediatric patients: a brief overview of progress in topical treatment.

Authors:  Serina Stretton; Usha Gopinathan; Mark D P Willcox
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

2.  A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.

Authors:  Tanweer S Zaidi; Gregory P Priebe; Gerald B Pier
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

3.  Antimicrobial efficacy and ocular cell toxicity from silver nanoparticles.

Authors:  Colleen M Santoro; Nicole L Duchsherer; David W Grainger
Journal:  Nanobiotechnology       Date:  2007-05-01

4.  Microbiota-driven immune cellular maturation is essential for antibody-mediated adaptive immunity to Staphylococcus aureus infection in the eye.

Authors:  Tanweer Zaidi; Tauqeer Zaidi; Colette Cywes-Bentley; Roger Lu; Gregory P Priebe; Gerald B Pier
Journal:  Infect Immun       Date:  2014-06-09       Impact factor: 3.441

5.  Chitosan-Based Intranasal Vaccine against Escherichia coli O157:H7.

Authors:  Tahere Doavi; Seyed Latif Mousavi; Mehdi Kamali; Jafar Amani; Mahdi Fasihi Ramandi
Journal:  Iran Biomed J       Date:  2016-01-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.